US7288609B1 - Coatings for drug delivery devices based on poly (orthoesters) - Google Patents

Coatings for drug delivery devices based on poly (orthoesters) Download PDF

Info

Publication number
US7288609B1
US7288609B1 US10/382,197 US38219703A US7288609B1 US 7288609 B1 US7288609 B1 US 7288609B1 US 38219703 A US38219703 A US 38219703A US 7288609 B1 US7288609 B1 US 7288609B1
Authority
US
United States
Prior art keywords
diol
poly
coating
group
glycol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/382,197
Inventor
Stephen D. Pacetti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abbott Cardiovascular Systems Inc
Original Assignee
Advanced Cardiovascular Systems Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advanced Cardiovascular Systems Inc filed Critical Advanced Cardiovascular Systems Inc
Priority to US10/382,197 priority Critical patent/US7288609B1/en
Assigned to ADVANCED CARDIOVASCULAR SYSTEMS, INC. reassignment ADVANCED CARDIOVASCULAR SYSTEMS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: PACETTI, STEPHEN D.
Priority to US11/859,372 priority patent/US7588794B2/en
Application granted granted Critical
Publication of US7288609B1 publication Critical patent/US7288609B1/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/002—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from unsaturated compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G2650/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G2650/28—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type
    • C08G2650/38—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group
    • C08G2650/42—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule characterised by the polymer type containing oxygen in addition to the ether group containing orthoester groups

Definitions

  • This invention is directed to coatings for implantable medical devices, such as drug eluting vascular stents.
  • Percutaneous transluminal coronary angioplasty is a procedure for treating heart disease.
  • a catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery.
  • the catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion.
  • the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall.
  • the balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
  • problems associated with the above procedures includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain vascular patency.
  • Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy.
  • stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway.
  • stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
  • Biological therapy can be achieved by medicating the stents.
  • Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results.
  • One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer. Once the stent has been implanted at the treatment site, the therapeutic substance has a sustained release profile from the polymer.
  • Non-fouling surface A surface that does not adsorb proteins, or that adsorbs only a minimal amount of proteins, is herein referred to as a “non-fouling” surface.
  • the embodiments of the present invention are directed to polymers and combination of polymers that satisfy this need.
  • a coating for medical devices comprises a polymer that is a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol.
  • the diketene acetal can be 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane; 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane; or mixtures thereof.
  • the hydroxylated functional compound can be poly(alkylene glycols), hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), or mixtures thereof.
  • Diols can be alkylene glycols, oligoalkylene glycols, cycloaliphatic diols, or mixtures thereof.
  • the coating comprises a polymer having the formula
  • a method for fabricating a polymer coating for a medical device comprises applying a polymer onto the surface of the device, wherein the polymer comprises a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol.
  • an implantable medical device is disclosed.
  • the implantable medical device is made of a polymer comprising a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol.
  • a coating for an implantable medical device can include an optional primer layer, a drug-polymer layer (also referred to as “reservoir” or “reservoir layer”) or a polymer-free drug layer, and an optional topcoat layer.
  • the drug-polymer layer serves as a reservoir for the drug.
  • the reservoir layer or the polymer-free drug layer can be applied directly onto the stent surface.
  • the optional primer layer can be applied on the stent surface to improve the adhesion of the drug-polymer layer or the polymer-free drug layer to the stent.
  • the optional topcoat layer which can be essentially free from any drugs, serves as a rate limiting membrane that helps to control the rate of release of the drug.
  • polyorthoesters are polymers that can be used to make any or all of the optional primer layer, the reservoir layer, and/or the optional topcoat layer.
  • at least one compound of Group I is reacted with at least one compound of Group II and at least one compound of Group III.
  • Groups I, II, and III are described below.
  • Ketenes are compounds having carbonyl bond and carbon-carbon double bond adjacent each other and can be generally described by the formula >C ⁇ C ⁇ O.
  • Diketenes consequently, are compounds comprising two ketene groups.
  • Diketene acetals include two reactive centers capable of reacting with two hydroxy functional molecules to serve as a linking agent.
  • Diketene acetals have a general formula (I)
  • R and R 1 can be, independently, unsubstituted or substituted straight-chained, branched, or cyclic, C 1 -C 8 alkyl radicals, or unsubstituted or substituted aryl radicals. Any suitable substitutent as selected by those having ordinary skill in the art can be present in the substituted radicals.
  • Suitable diketene acetals described by formula (I) include 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane (DETOSU), 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane (DPTOSH), 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane, 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane and mixtures thereof.
  • DPTOSH 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane
  • both R and R 1 are n-butyl groups.
  • Group II comprises hydroxylated compounds having non-fouling characteristics.
  • the hydroxylated compounds can react with the diketene acetal to form soft segments of polyorthoesters.
  • the soft segments can have a glass transition temperature (T g ) below body temperature, e.g., for humans, below about 37° C.
  • T g glass transition temperature
  • the hydroxyl group can be located in a terminal or non-terminal position of the molecule.
  • Suitable hydroxy functional compounds include poly(alkylene glycols), for example, poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG) or poly(tetramethylene glycol), PLURONIC surfactants, hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid and its derivatives such as sodium hyaluronate, and poly(2-hydroxyethyl methacrylate), or mixtures thereof.
  • PLURONIC is a trade name of poly(ethylene oxide-co-propylene oxide) and is available from BASF Corp. of Parsippany, N.J.
  • the molecular weight of a suitable compound of Group II can be such so as to allow passage of the released molecule through the kidneys, for example, below 40,000 Daltons, such as between about 300 and 20,000 Daltons.
  • R 2 is the polymethylene structure (CH 2 ) x , where “x” is an integer.
  • x is an integer.
  • Group III comprises short-to-moderate-length aliphatic or cycloaliphatic diols or blends or combinations thereof.
  • the diols can react with the diketene acetal to form hard segments of polyorthoesters.
  • the hard segments can either have some crystallinity or have a T g above body temperature, e.g., about 37° C.
  • the hard segments can serve as quasi cross-linking agents both strengthening the final polyorthoester and enabling the polyorthoester to behave as an elastomer.
  • Suitable diols include alkylene glycols, for example, C 2 through C 16 ⁇ , ⁇ -glycols such as ethylene glycol (C 2 ), propylene glycol (C 3 ), butane-1,4-diol (C 4 ), pentane-1,5-diol (C 5 ), hexane-1,6-diol (C 6 ), heptane-1,7-diol (C 7 ), octane-1,8-diol (C 8 ), nonane-1,9-diol (C 9 ), decane-1,10-diol (C 10 ), undecane-1,11-diol (C 11 ), dodecane-1,12-diol (C 12 ), tridecane-1,13-diol (C 13 ), tetradecane-1,14-diol (C 14 ), pentadecane-1,15-dio
  • aliphatic diols that can be used include oligoalkylene glycols such as diethylene glycol, trimethylene glycol, tetramethylene glycol, tetraethylene glycol, poly(tetraethylene glycol), poly(propylene glycol), and mixtures thereof.
  • suitable cycloaliphatic diols include trans-cyclohexanedimethanol, 1,4-cyclohexanediol, and mixtures thereof.
  • R 3 represents an aliphatic or cycloaliphatic group.
  • R 3 is the poly- or oligomethylene structure (CH 2 ) y , where “y” is an integer from 2 to 16.
  • y is an integer from 2 to 16.
  • one way of preparing polyorthoesters is to use a two-step synthetic process.
  • the first step includes reacting the whole amount of diketene acetal of Group I with a hydroxy functional compound of Group II.
  • the reaction (“reaction 1”) can be conducted in an anhydrous environment at an elevated temperature, for example, about 80° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid.
  • the second step includes adding a diol of Group III to the product of reaction 1, which can be conducted at an elevated temperature, for example, about 80° C.
  • a polyorthoester can be obtained, the polyorthoester having the general formula (V):
  • R, R 1 , R 2 , and R 3 are as described above; m, n, p, and q are all integers, where the value of m is from about 5 to about 500, the value of n is from about 2 to about 350, the value of p is from about 1 to about 20, and the value of q is from about 10 to about 550.
  • the polyorthoester described by formula (V) can have molecular weight within a range of from about 20,000 to about 200,000 Daltons.
  • Polyorthoesters of this invention can be used for making stent coatings.
  • the coating can be applied onto the stent by a commonly used method known to one of ordinary skill in the art, for instance, by spraying, dipping or molding.
  • the polyorthoesters can be used to fabricate a primer layer, a reservoir layer or a topcoat layer.
  • the polyorthoesters can be used alone or in combination with other suitable polymers.
  • Poly(ethylene-co-vinyl alcohol) (EVAL) is one example of a polymer than can be employed.
  • EVAL is a product of hydrolysis of ethylene-vinyl acetate copolymers and may also be a terpolymer including up to 5 molar % of units derived from styrene, propylene and other suitable unsaturated monomers. EVAL is available from Sigma-Aldrich Co. of Milwaukee, Wis.
  • PEO/PLA polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene fluoride and polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins (such as ethylene-methyl methacrylate copolymers, acryl
  • the drug can include any substance capable of exerting a therapeutic or prophylactic effect for a patient.
  • the drug may include small molecule drugs, peptides, proteins, oligonucleotides, and the like.
  • the drug could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.
  • drugs examples include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich, or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I 1 , actinomycin X 1 , and actinomycin C 1 .
  • the active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g.
  • TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.
  • docetaxel e.g. Taxotere®, from Aventis S. A., Frankfurt, Germany
  • methotrexate azathioprine
  • vincristine vincristine
  • vinblastine a cell line
  • fluorouracil a cell line
  • doxorubicin hydrochloride e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.
  • mitomycin e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.
  • antiplatelets examples include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as AngiomaxTM (Biogen, Inc., Cambridge, Mass.).
  • AngiomaxTM Biogen, Inc., Cambridge, Mass.
  • cytostatic or antiproliferative agents examples include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g.
  • calcium channel blockers such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide.
  • PDGF Platelet-Derived Growth Factor
  • an antiallergic agent is permirolast potassium.
  • Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
  • the stent, or other implantable medical device can be used in any part of the vascular system, including neurological, carotid, coronary, renal, aortic, iliac, femoral or any other part of the peripheral vasculature.
  • implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts).
  • the coating can also be used with artificial heart valves, cerebrospinal fluid shunts, coronary shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation).
  • the underlying structure of the device can be of virtually any design.
  • the device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof.
  • MP35N and MP20N are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
  • the entire stent can be made of a poly(ortho ester).
  • a poly(ortho ester) stent is expected to be completely biologically degradable and biologically absorbable.
  • the poly(ortho ester) stent can be gradually hydrolyzed as a result of its contact with blood followed by absorption by the body.
  • a drug for example, EVEROLIMUS can be optionally incorporated into the poly(ortho ester) stent by mixing the drug with poly(ortho ester) followed by forming the stent out of the drug-poly(ortho ester) mixture.
  • the drug can be applied on the surface of the poly(ortho ester) stent after the poly(ortho ester) stent has been formed.
  • the drug-polymer solution can be prepared, the solution containing the drug and poly(ortho ester) in a mass ratio of about 1:3. The solution can be applied onto the surface of the poly(ortho ester) stent followed by drying.
  • PEG having a molecular weight (M w ) of about 1,000 can be placed into a 1-liter round bottom flask equipped with a mechanical stirrer.
  • PEG can be treated to remove water by being heated to about 80° C. using an oil bath, while being stirred under vacuum of about 25 mm Hg.
  • About 400 g of tetrahydrofuran (THF) and about 27.83 g (131 mmol) of DETOSU can be added to the flask and dissolved with continued stirring.
  • a solution of p-toluenesulfonic acid in THF having concentration of about 25 g/l can be prepared and about 15 drops of this solution can be added to the contents of the flask.
  • the stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C.
  • About 8.08 g (106 mmol) of propylene glycol can then be added to the flask, and the stirring can be continued for about 1 more hour while the contents of the flask are kept at about 80° C.
  • the reaction mixture then can be cooled and about 1 liter of hexane can be added.
  • the polyorthoester PEG-DETOSU-PG can be collected by filtration.
  • the polymer can then be purified by dissolution in dry methanol and precipitation with hexane.
  • the ratio between the soft and hard segments in the polymer is about 1:1 by mass.
  • PEG having a M w of about 2,000 can be treated to remove water as described in Example 1.
  • About 400 g of THF and about 27.83 g (131 mmol) of DETOSU can be added to the flask and dissolved with continued stirring.
  • About 10 drops of the solution of p-toluenesulfonic acid described in Example 1 can be added to the contents of the flask.
  • the stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C.
  • About 8.53 g (16.67 mmol) of 1,4-butanediol can then be added to the flask, and the stirring can continue for about 1 more hour while the contents of the flask are kept at about 80° C.
  • the reaction mixture can then be cooled and about 1 liter of hexane can be added.
  • the polyorthoester PEG-DETOSU-BD can be collected by filtration.
  • the polymer can then be purified as described in Example 1.
  • the ratio between the soft and hard segments in the polymer is about 7:3 by mass.
  • PEG-DETOSU-BD is expected to be softer, more hydrophilic, more swellable in water, and is expected to biodegrade faster.
  • PEG having a M w of about 300 can be treated to remove water as described in Example 1.
  • About 400 g of THF and about 59.47 g (200.9 mmol) of DPTOSH can be added to the flask and dissolved with continued stirring.
  • About 20 drops of the solution of p-toluenesulfonic acid described in Example 1 can be added to the contents of the flask. The stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C.
  • a first composition can be prepared by mixing the following components:
  • the first composition can be applied onto the surface of a bare 12 mm TETRA stent by spraying and dried to form a primer layer.
  • An EFD spray head can be used, having a 0.014 inch round nozzle tip and a 0.028 inch round air cap with a feed pressure of about 0.2 atm (3 psi) and an atomization pressure of between about 1 atm and 1.3 atm (15 to 20 psi).
  • the total amount of solids of the primer layer can be about 40 micrograms ( ⁇ g).
  • the stents can be baked at about 55° C. for about one hour. “Solids” means the amount of dry residue deposited on the stent after all volatile organic compounds (e.g. the solvent) have been removed.
  • a second composition can be prepared by mixing the following components:
  • the second composition can be applied onto the dried primer to form a reservoir layer, using the same spraying technique and equipment used for applying the primer layer.
  • Solvent can be removed by baking at about 50° C. for about one hour.
  • the total amount of solids of the drug-polymer layer can be about 320 ⁇ g.
  • a third composition can be prepared by mixing the following components:
  • the third composition can be applied onto the dried reservoir layer to form a topcoat layer.
  • Solvent can be removed by baking at 50° C. for one hour.
  • the total amount of solids of the topcoat layer can be about 100 ⁇ g.
  • a poly(ortho ester) can be synthesized of DETOSU and a diol component.
  • the diol component can comprise a mixture of trans-cyclohexanediol and 1,6-hexanediol in the molar ratio between trans-cyclohexanediol and 1,6-hexanediol being about 7:3.
  • Synthesis as described in Example 1 can be used.
  • the poly(ortho ester) can be dissolved in a blend of trichloroethane and tetrahydrofuran solvents having about 1:1 mass ratio between the solvents.
  • the concentration of the poly(ortho ester) solution can be about 6% by mass.
  • EVEROLIMUS can then be added to the poly(ortho ester) solution to form a drug-polymer solution.
  • the mass ratio between EVEROLIMUS and poly(ortho ester) in the drug-polymer solution can be about 1:9.
  • a TEFLON rod having a diameter of about 3 mm can be dip coated with the poly(ortho ester) solution, in an automated fashion, using dip coating techniques and equipment known to those having ordinary skill in the art. Between dips, the rod can be dried at about 40° C. for about 1 minute. After a wall thickness of about 0.2 mm has been obtained, all of the solvent can be removed by baking in a vacuum oven overnight at ambient temperature.
  • the polymer tube can be slipped off the TEFLON rod and a MULTI-LINK stent pattern can be cut into the polymer tube using a laser cutter.
  • the laser cutter can include an eximer laser and CNC mechanism to position the stent under the laser.
  • the stent pattern can be cut out in a configuration corresponding to the fully expanded state.
  • the self-expanding polymer stent can be then physically compressed and loaded onto a delivery catheter equipped with a guidewire lumen and retractable sleeve for deployment of the stent. Using standard percutaneous techniques, this delivery catheter can be used to deliver and deploy the stent to stenosed vasculature where an ultimate size of approximately 3 mm is desired.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Materials For Medical Uses (AREA)

Abstract

A polymer coating for implantable medical devices based on polyorthoesters and methods for fabricating the coating are disclosed. The implantable medical devices made of polyorthoesters and methods for fabricating thereof are also disclosed.

Description

BACKGROUND OF THE INVENTION
1. Field of the Invention
This invention is directed to coatings for implantable medical devices, such as drug eluting vascular stents.
2. Description of the State of the Art
Percutaneous transluminal coronary angioplasty (PTCA) is a procedure for treating heart disease. A catheter assembly having a balloon portion is introduced percutaneously into the cardiovascular system of a patient via the brachial or femoral artery. The catheter assembly is advanced through the coronary vasculature until the balloon portion is positioned across the occlusive lesion. Once in position across the lesion, the balloon is inflated to a predetermined size to radially compress against the atherosclerotic plaque of the lesion to remodel the lumen wall. The balloon is then deflated to a smaller profile to allow the catheter to be withdrawn from the patient's vasculature.
Problems associated with the above procedures includes formation of intimal flaps or torn arterial linings which can collapse and occlude the conduit after the balloon is deflated. Moreover, thrombosis and restenosis of the artery may develop over several months after the procedure, which may require another angioplasty procedure or a surgical by-pass operation. To reduce the partial or total occlusion of the artery by the collapse of arterial lining and to reduce the chance of the development of thrombosis and restenosis, a stent is implanted in the lumen to maintain vascular patency.
Stents are used not only as a mechanical intervention but also as a vehicle for providing biological therapy. As a mechanical intervention, stents act as scaffoldings, functioning to physically hold open and, if desired, to expand the wall of the passageway. Typically, stents are capable of being compressed, so that they can be inserted through small vessels via catheters, and then expanded to a larger diameter once they are at the desired location. Examples in patent literature disclosing stents which have been applied in PTCA procedures include stents illustrated in U.S. Pat. No. 4,733,665 issued to Palmaz, U.S. Pat. No. 4,800,882 issued to Gianturco, and U.S. Pat. No. 4,886,062 issued to Wiktor.
Biological therapy can be achieved by medicating the stents. Medicated stents provide for the local administration of a therapeutic substance at the diseased site. In order to provide an efficacious concentration to the treated site, systemic administration of such medication often produces adverse or toxic side effects for the patient. Local delivery is a preferred method of treatment in that smaller total levels of medication are administered in comparison to systemic dosages, but are concentrated at a specific site. Local delivery thus produces fewer side effects and achieves more favorable results. One proposed method for medicating stents involves the use of a polymeric carrier coated onto the surface of a stent. A solution which includes a solvent, a polymer dissolved in the solvent, and a therapeutic substance dispersed in the blend is applied to the stent. The solvent is allowed to evaporate, leaving on the stent surface a coating of the polymer and the therapeutic substance impregnated in the polymer. Once the stent has been implanted at the treatment site, the therapeutic substance has a sustained release profile from the polymer.
Local administration of therapeutic agents via stents has shown some favorable results in reducing restenosis. However, the biological compatibility of stent coatings or stents can be improved. For example, the ability of the surface of the stent coating to repel proteins can be improved. A surface that does not adsorb proteins, or that adsorbs only a minimal amount of proteins, is herein referred to as a “non-fouling” surface.
Accordingly, there is a need to have stent coatings with improved biological compatibility. The embodiments of the present invention are directed to polymers and combination of polymers that satisfy this need.
SUMMARY
According to one embodiment of this invention, a coating for medical devices is provided. The coating comprises a polymer that is a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol. The diketene acetal can be 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane; 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane; or mixtures thereof. The hydroxylated functional compound can be poly(alkylene glycols), hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), or mixtures thereof. Diols can be alkylene glycols, oligoalkylene glycols, cycloaliphatic diols, or mixtures thereof.
According to another embodiment of the present invention, the coating comprises a polymer having the formula
Figure US07288609-20071030-C00001
wherein:
    • R and R1 are each, independently, an unsubstituted or substituted straight-chained, branched, or cyclic, C1-C8 alkyl radical, or unsubstituted or substituted aryl radical;
    • R2 is the repeating unit of the moiety providing the polymer with non-fouling characteristics;
    • R3 is an aliphatic or cycloaliphatic group;
    • m, n, p, and q are all integers, where the value of m is from 5 to 500, the value of n is from 2 to 350, the value of p is from 1 to 20, and the value of q is from 10 to 550.
According to yet another embodiment of the present invention, a method for fabricating a polymer coating for a medical device is provided. The method comprises applying a polymer onto the surface of the device, wherein the polymer comprises a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol.
According to another embodiment of the present invention, an implantable medical device is disclosed. The implantable medical device is made of a polymer comprising a product of co-polycondensation of a diketene acetal, a hydroxylated functional compound and a diol.
DETAILED DESCRIPTION
A coating for an implantable medical device, such as a stent, according to one embodiment of the present invention, can include an optional primer layer, a drug-polymer layer (also referred to as “reservoir” or “reservoir layer”) or a polymer-free drug layer, and an optional topcoat layer. The drug-polymer layer serves as a reservoir for the drug. The reservoir layer or the polymer-free drug layer can be applied directly onto the stent surface. The optional primer layer can be applied on the stent surface to improve the adhesion of the drug-polymer layer or the polymer-free drug layer to the stent. The optional topcoat layer, which can be essentially free from any drugs, serves as a rate limiting membrane that helps to control the rate of release of the drug.
According to the present invention, polyorthoesters are polymers that can be used to make any or all of the optional primer layer, the reservoir layer, and/or the optional topcoat layer. To obtain polyorthoesters that are suitable for making stent coatings, at least one compound of Group I is reacted with at least one compound of Group II and at least one compound of Group III. Groups I, II, and III are described below.
Group I. Diketene Acetals
Ketenes are compounds having carbonyl bond and carbon-carbon double bond adjacent each other and can be generally described by the formula >C═C═O. Diketenes, consequently, are compounds comprising two ketene groups. Diketene acetals include two reactive centers capable of reacting with two hydroxy functional molecules to serve as a linking agent. Diketene acetals have a general formula (I)
Figure US07288609-20071030-C00002
where R and R1 can be, independently, unsubstituted or substituted straight-chained, branched, or cyclic, C1-C8 alkyl radicals, or unsubstituted or substituted aryl radicals. Any suitable substitutent as selected by those having ordinary skill in the art can be present in the substituted radicals.
Examples of suitable diketene acetals described by formula (I) that can be used include 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane (DETOSU), 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane (DPTOSH), 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane, 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane and mixtures thereof. Those having ordinary skill in the art can synthesize diketene acetals, as described in the literature, for example, in Heller J., Adv. Polymer Sci., vol. 107, pp. 41-92 (1993).
Formula (I) describes the molecule of DETOSU where both R and R1 are methyl groups. Consequently, DETOSU has the formula (II):
Figure US07288609-20071030-C00003
For DPTOSH, both R and R1 are n-butyl groups.
Group II. Hydroxy Functional Compounds
Group II comprises hydroxylated compounds having non-fouling characteristics. The hydroxylated compounds can react with the diketene acetal to form soft segments of polyorthoesters. The soft segments can have a glass transition temperature (Tg) below body temperature, e.g., for humans, below about 37° C. The hydroxyl group can be located in a terminal or non-terminal position of the molecule. Examples of suitable hydroxy functional compounds include poly(alkylene glycols), for example, poly(ethylene glycol) (PEG), poly(propylene glycol) (PPG) or poly(tetramethylene glycol), PLURONIC surfactants, hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid and its derivatives such as sodium hyaluronate, and poly(2-hydroxyethyl methacrylate), or mixtures thereof. PLURONIC is a trade name of poly(ethylene oxide-co-propylene oxide) and is available from BASF Corp. of Parsippany, N.J.
The molecular weight of a suitable compound of Group II can be such so as to allow passage of the released molecule through the kidneys, for example, below 40,000 Daltons, such as between about 300 and 20,000 Daltons.
Compounds of Group II can be described by the general formula (III):
Figure US07288609-20071030-C00004
where “m” is an integer, and —R2—O— represents the moiety of compound (III) providing non-fouling characteristics. For example, when compound (III) is a poly(alkylene glycol), R2 is the polymethylene structure (CH2)x, where “x” is an integer. To illustrate for compound (III) being PEG, x=2.
Group III. Diols
Group III comprises short-to-moderate-length aliphatic or cycloaliphatic diols or blends or combinations thereof. The diols can react with the diketene acetal to form hard segments of polyorthoesters. The hard segments can either have some crystallinity or have a Tg above body temperature, e.g., about 37° C. The hard segments can serve as quasi cross-linking agents both strengthening the final polyorthoester and enabling the polyorthoester to behave as an elastomer. Examples of suitable diols include alkylene glycols, for example, C2 through C16 α,ω-glycols such as ethylene glycol (C2), propylene glycol (C3), butane-1,4-diol (C4), pentane-1,5-diol (C5), hexane-1,6-diol (C6), heptane-1,7-diol (C7), octane-1,8-diol (C8), nonane-1,9-diol (C9), decane-1,10-diol (C10), undecane-1,11-diol (C11), dodecane-1,12-diol (C12), tridecane-1,13-diol (C13), tetradecane-1,14-diol (C14), pentadecane-1,15-diol (C15), hexadecane-1,16-diol (C16), or mixtures thereof, or other alkylene glycols, for example, butane-1,3-diol, pentane-2,4-diol, hexane-2,5-diol, or mixtures thereof. Other aliphatic diols that can be used include oligoalkylene glycols such as diethylene glycol, trimethylene glycol, tetramethylene glycol, tetraethylene glycol, poly(tetraethylene glycol), poly(propylene glycol), and mixtures thereof. Examples of suitable cycloaliphatic diols include trans-cyclohexanedimethanol, 1,4-cyclohexanediol, and mixtures thereof.
Compounds of Group III can be described by the general formula (IV):
Figure US07288609-20071030-C00005
where R3 represents an aliphatic or cycloaliphatic group. For example, when compound (IV) is an alkylene glycol, R3 is the poly- or oligomethylene structure (CH2)y, where “y” is an integer from 2 to 16. To illustrate, when compound (IV) is ethylene glycol, y=2. In case of propylene glycol, y=3.
According to embodiments of the present invention, one way of preparing polyorthoesters is to use a two-step synthetic process. The first step includes reacting the whole amount of diketene acetal of Group I with a hydroxy functional compound of Group II. The reaction (“reaction 1”) can be conducted in an anhydrous environment at an elevated temperature, for example, about 80° C., and can be catalyzed by a strong acid or base, e.g., p-toluenesulfonic acid. The second step includes adding a diol of Group III to the product of reaction 1, which can be conducted at an elevated temperature, for example, about 80° C. As a result of the two-step process described above, a polyorthoester can be obtained, the polyorthoester having the general formula (V):
Figure US07288609-20071030-C00006
where R, R1, R2, and R3 are as described above; m, n, p, and q are all integers, where the value of m is from about 5 to about 500, the value of n is from about 2 to about 350, the value of p is from about 1 to about 20, and the value of q is from about 10 to about 550. The polyorthoester described by formula (V) can have molecular weight within a range of from about 20,000 to about 200,000 Daltons.
Polyorthoesters of this invention can be used for making stent coatings. The coating can be applied onto the stent by a commonly used method known to one of ordinary skill in the art, for instance, by spraying, dipping or molding. The polyorthoesters can be used to fabricate a primer layer, a reservoir layer or a topcoat layer. The polyorthoesters can be used alone or in combination with other suitable polymers. Poly(ethylene-co-vinyl alcohol) (EVAL) is one example of a polymer than can be employed. EVAL is a product of hydrolysis of ethylene-vinyl acetate copolymers and may also be a terpolymer including up to 5 molar % of units derived from styrene, propylene and other suitable unsaturated monomers. EVAL is available from Sigma-Aldrich Co. of Milwaukee, Wis.
Representative examples of other suitable polymers include poly(hydroxyvalerate), poly(L-lactic acid), polycaprolactone, poly(lactide-co-glycolide), poly(hydroxybutyrate), poly(hydroxybutyrate-co-valerate), polydioxanone, polyorthoester, polyanhydride, poly(glycolic acid), poly(D,L-lactic acid), poly(glycolic acid-co-trimethylene carbonate), polyphosphoester, polyphosphoester urethane; poly(amino acids), cyanoacrylates, poly(trimethylene carbonate), poly(iminocarbonate), co-poly(ether-esters) (e.g. PEO/PLA), polyalkylene oxalates, polyphosphazenes, biomolecules (such as fibrin, fibrinogen, cellulose, starch, collagen and hyaluronic acid), polyurethanes, silicones, polyesters, polyolefins, polyisobutylene and ethylene-alphaolefin copolymers, acrylic polymers and copolymers, vinyl halide polymers and copolymers (such as polyvinyl chloride), polyvinyl ethers (such as polyvinyl methyl ether), polyvinylidene halides (such as polyvinylidene fluoride and polyvinylidene chloride), polyacrylonitrile, polyvinyl ketones, polyvinyl aromatics (such as polystyrene), polyvinyl esters (such as polyvinyl acetate), copolymers of vinyl monomers with each other and olefins (such as ethylene-methyl methacrylate copolymers, acrylonitrile-styrene copolymers, ABS resins, and ethylene-vinyl acetate copolymers), polyamides (such as Nylon 66 and polycaprolactam), alkyd resins, other polycarbonates, polyoxymethylenes, polyimides, polyethers, epoxy resins, other polyurethanes, rayon, rayon-triacetate, cellulose, cellulose acetate, cellulose butyrate, cellulose acetate butyrate, cellophane, cellulose nitrate, cellulose propionate, cellulose ethers, soluble fluorinated polymers and carboxymethyl cellulose.
The drug can include any substance capable of exerting a therapeutic or prophylactic effect for a patient. The drug may include small molecule drugs, peptides, proteins, oligonucleotides, and the like. The drug could be designed, for example, to inhibit the activity of vascular smooth muscle cells. It can be directed at inhibiting abnormal or inappropriate migration and/or proliferation of smooth muscle cells to inhibit restenosis.
Examples of drugs include antiproliferative substances such as actinomycin D, or derivatives and analogs thereof (manufactured by Sigma-Aldrich, or COSMEGEN available from Merck). Synonyms of actinomycin D include dactinomycin, actinomycin IV, actinomycin I1, actinomycin X1, and actinomycin C1. The active agent can also fall under the genus of antineoplastic, anti-inflammatory, antiplatelet, anticoagulant, antifibrin, antithrombin, antimitotic, antibiotic, antiallergic and antioxidant substances. Examples of such antineoplastics and/or antimitotics include paclitaxel (e.g. TAXOL® by Bristol-Myers Squibb Co., Stamford, Conn.), docetaxel (e.g. Taxotere®, from Aventis S. A., Frankfurt, Germany) methotrexate, azathioprine, vincristine, vinblastine, fluorouracil, doxorubicin hydrochloride (e.g. Adriamycin® from Pharmacia & Upjohn, Peapack N.J.), and mitomycin (e.g. Mutamycin® from Bristol-Myers Squibb Co., Stamford, Conn.). Examples of such antiplatelets, anticoagulants, antifibrin, and antithrombins include sodium heparin, low molecular weight heparins, heparinoids, hirudin, argatroban, forskolin, vapiprost, prostacyclin and prostacyclin analogues, dextran, D-phe-pro-arg-chloromethylketone (synthetic antithrombin), dipyridamole, glycoprotein IIb/IIIa platelet membrane receptor antagonist antibody, recombinant hirudin, and thrombin inhibitors such as Angiomax™ (Biogen, Inc., Cambridge, Mass.). Examples of such cytostatic or antiproliferative agents include angiopeptin, angiotensin converting enzyme inhibitors such as captopril (e.g. Capoten® and Capozide® from Bristol-Myers Squibb Co., Stamford, Conn.), cilazapril or lisinopril (e.g. Prinivil® and Prinzide® from Merck & Co., Inc., Whitehouse Station, N.J.); calcium channel blockers (such as nifedipine), colchicine, fibroblast growth factor (FGF) antagonists, fish oil (omega 3-fatty acid), histamine antagonists, lovastatin (an inhibitor of HMG-CoA reductase, a cholesterol lowering drug, brand name Mevacor® from Merck & Co., Inc., Whitehouse Station, N.J.), monoclonal antibodies (such as those specific for Platelet-Derived Growth Factor (PDGF) receptors), nitroprusside, phosphodiesterase inhibitors, prostaglandin inhibitors, suramin, serotonin blockers, steroids, thioprotease inhibitors, triazolopyrimidine (a PDGF antagonist), and nitric oxide. An example of an antiallergic agent is permirolast potassium. Other therapeutic substances or agents which may be appropriate include alpha-interferon, genetically engineered epithelial cells, tacrolimus, dexamethasone, and rapamycin and structural derivatives or functional analogs thereof, such as 40-O-(2-hydroxy)ethyl-rapamycin (known by the trade name of EVEROLIMUS available from Novartis), 40-O-(3-hydroxy)propyl-rapamycin, 40-O-[2-(2-hydroxy)ethoxy]ethyl-rapamycin, and 40-O-tetrazole-rapamycin.
The stent, or other implantable medical device can be used in any part of the vascular system, including neurological, carotid, coronary, renal, aortic, iliac, femoral or any other part of the peripheral vasculature. The are no limitations on the size of the stent, its length, diameter, strut thickness or pattern. Examples of such implantable devices include self-expandable stents, balloon-expandable stents, stent-grafts, grafts (e.g., aortic grafts). The coating can also be used with artificial heart valves, cerebrospinal fluid shunts, coronary shunts, pacemaker electrodes, and endocardial leads (e.g., FINELINE and ENDOTAK, available from Guidant Corporation). The underlying structure of the device can be of virtually any design. The device can be made of a metallic material or an alloy such as, but not limited to, cobalt chromium alloy (ELGILOY), stainless steel (316L), “MP35N,” “MP20N,” ELASTINITE (Nitinol), tantalum, nickel-titanium alloy, platinum-iridium alloy, gold, magnesium, or combinations thereof. “MP35N” and “MP20N” are trade names for alloys of cobalt, nickel, chromium and molybdenum available from standard Press Steel Co., Jenkintown, Pa. “MP35N” consists of 35% cobalt, 35% nickel, 20% chromium, and 10% molybdenum. “MP20N” consists of 50% cobalt, 20% nickel, 20% chromium, and 10% molybdenum. Devices made from bioabsorbable or biostable polymers could also be used with the embodiments of the present invention.
According to an embodiment of the present invention, the entire stent can be made of a poly(ortho ester). Such stent is expected to be completely biologically degradable and biologically absorbable. For example, the poly(ortho ester) stent can be gradually hydrolyzed as a result of its contact with blood followed by absorption by the body.
A drug, for example, EVEROLIMUS can be optionally incorporated into the poly(ortho ester) stent by mixing the drug with poly(ortho ester) followed by forming the stent out of the drug-poly(ortho ester) mixture. Alternatively, the drug can be applied on the surface of the poly(ortho ester) stent after the poly(ortho ester) stent has been formed. To apply the drug on the surface of the poly(ortho ester) stent, the drug-polymer solution can be prepared, the solution containing the drug and poly(ortho ester) in a mass ratio of about 1:3. The solution can be applied onto the surface of the poly(ortho ester) stent followed by drying.
The following examples demonstrate some embodiments of the present invention.
EXAMPLE 1 Synthesis of Poly(ethylene glycol)-co-3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane-co-propylene glycol (PEG-DETOSU-PG)
About 25 g (12.5 mmol) of PEG having a molecular weight (Mw) of about 1,000 can be placed into a 1-liter round bottom flask equipped with a mechanical stirrer. PEG can be treated to remove water by being heated to about 80° C. using an oil bath, while being stirred under vacuum of about 25 mm Hg. About 400 g of tetrahydrofuran (THF) and about 27.83 g (131 mmol) of DETOSU can be added to the flask and dissolved with continued stirring. A solution of p-toluenesulfonic acid in THF having concentration of about 25 g/l can be prepared and about 15 drops of this solution can be added to the contents of the flask. The stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C. About 8.08 g (106 mmol) of propylene glycol can then be added to the flask, and the stirring can be continued for about 1 more hour while the contents of the flask are kept at about 80° C. The reaction mixture then can be cooled and about 1 liter of hexane can be added. As a result, the polyorthoester PEG-DETOSU-PG, can be collected by filtration. The polymer can then be purified by dissolution in dry methanol and precipitation with hexane. The ratio between the soft and hard segments in the polymer is about 1:1 by mass.
EXAMPLE 2 Synthesis of Poly(ethylene glycol)-co-3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane-co-1,4-butanediol (PEG-DETOSU-BD)
About 25 g (12.5 mmol) of PEG having a Mw of about 2,000 can be treated to remove water as described in Example 1. About 400 g of THF and about 27.83 g (131 mmol) of DETOSU can be added to the flask and dissolved with continued stirring. About 10 drops of the solution of p-toluenesulfonic acid described in Example 1 can be added to the contents of the flask. The stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C. About 8.53 g (16.67 mmol) of 1,4-butanediol can then be added to the flask, and the stirring can continue for about 1 more hour while the contents of the flask are kept at about 80° C. The reaction mixture can then be cooled and about 1 liter of hexane can be added. As a result, the polyorthoester PEG-DETOSU-BD, can be collected by filtration. The polymer can then be purified as described in Example 1. The ratio between the soft and hard segments in the polymer is about 7:3 by mass. Compared to PEG-DETOSU-PG described in Example 1, PEG-DETOSU-BD is expected to be softer, more hydrophilic, more swellable in water, and is expected to biodegrade faster.
EXAMPLE 3 Synthesis of Poly(ethylene glycol)-co-3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane-co-1,6-hexanediol (PEG-DPTOSH-HD)
About 25 g (83.3 mmol) of PEG having a Mw of about 300 can be treated to remove water as described in Example 1. About 400 g of THF and about 59.47 g (200.9 mmol) of DPTOSH can be added to the flask and dissolved with continued stirring. About 20 drops of the solution of p-toluenesulfonic acid described in Example 1 can be added to the contents of the flask. The stirring can continue for about 1 hour while the contents of the flask are maintained at about 80° C. About 14.21 g (122.5 mmol) of 1,6-hexanediol can then be added to the flask, and the stirring can continue for about 1 more hour while the contents of the flask are kept at about 80° C. The reaction mixture can then be cooled and about 1 liter of hexane can be added. As a result, the polyorthoester PEG-DPTOSH-HD, can be collected by filtration. The polymer can then be purified as described in Example 1. The ratio between the soft and hard segments in the polymer is about 1:1 by mass. Compared to PEG-DETOSU-PG described in Example 1, PEG-DPTOSH-HD has more hydrophobic diketene acetal and shorter PEG chains. Consequently, PEG-DPTOSH-HD is expected to be harder, more hydrophobic, adsorb less water, and is expected to biodegrade more slowly.
Structure of the polyorthoesters of Examples 1-3 described by formula (V) can be summarized as shown in Table 1.
TABLE 1
Structure Polyorthoesters of Examples 1-3
Figure US07288609-20071030-C00007
No. Polyorthoester R R1 R2 R3 m*) n*) p*) q*)
1 PEG-DETOSU-PG CH3 CH3 (CH2)2 (CH2)3 22 25 1 106
2 PEG-DETOSU-BD CH3 CH3 (CH2)2 (CH2)4 45 13 1 17
3 PEG-DPTOSH-HD n-C4H9 n-C4H9 (CH2)2 (CH2)6 6 83 1 123
*)The values of m, n, p, and q are rounded to the nearest integer
EXAMPLE 4
A first composition can be prepared by mixing the following components:
(a) about 2.0 mass % of poly(caprolactone); and
(b) the balance, a blend of the solvents THF and xylene at a mass ratio of THF to xylene of about 3:1.
The first composition can be applied onto the surface of a bare 12 mm TETRA stent by spraying and dried to form a primer layer. An EFD spray head can be used, having a 0.014 inch round nozzle tip and a 0.028 inch round air cap with a feed pressure of about 0.2 atm (3 psi) and an atomization pressure of between about 1 atm and 1.3 atm (15 to 20 psi). The total amount of solids of the primer layer can be about 40 micrograms (μg). After spraying, the stents can be baked at about 55° C. for about one hour. “Solids” means the amount of dry residue deposited on the stent after all volatile organic compounds (e.g. the solvent) have been removed.
A second composition can be prepared by mixing the following components:
(a) about 2 mass % of poly(D,L-lactide);
(b) about 1 mass % of EVEROLIMUS; and
(c) the balance, a solvent blend of acetone and trichloroethane at a mass ratio of about 1:1.
The second composition can be applied onto the dried primer to form a reservoir layer, using the same spraying technique and equipment used for applying the primer layer. Solvent can be removed by baking at about 50° C. for about one hour. The total amount of solids of the drug-polymer layer can be about 320 μg.
A third composition can be prepared by mixing the following components:
(a) about 2 mass % of PEG-DETOSU-BD obtained as described in Example 2;
(b) the balance, a solvent blend of acetone and cyclohexanone at a mass ratio of about 1:1.
The third composition can be applied onto the dried reservoir layer to form a topcoat layer. Solvent can be removed by baking at 50° C. for one hour. The total amount of solids of the topcoat layer can be about 100 μg.
EXAMPLE 5
A poly(ortho ester) can be synthesized of DETOSU and a diol component. The diol component can comprise a mixture of trans-cyclohexanediol and 1,6-hexanediol in the molar ratio between trans-cyclohexanediol and 1,6-hexanediol being about 7:3. Synthesis as described in Example 1 can be used. The poly(ortho ester) can be dissolved in a blend of trichloroethane and tetrahydrofuran solvents having about 1:1 mass ratio between the solvents. The concentration of the poly(ortho ester) solution can be about 6% by mass. EVEROLIMUS can then be added to the poly(ortho ester) solution to form a drug-polymer solution. The mass ratio between EVEROLIMUS and poly(ortho ester) in the drug-polymer solution can be about 1:9.
A TEFLON rod having a diameter of about 3 mm can be dip coated with the poly(ortho ester) solution, in an automated fashion, using dip coating techniques and equipment known to those having ordinary skill in the art. Between dips, the rod can be dried at about 40° C. for about 1 minute. After a wall thickness of about 0.2 mm has been obtained, all of the solvent can be removed by baking in a vacuum oven overnight at ambient temperature.
The polymer tube can be slipped off the TEFLON rod and a MULTI-LINK stent pattern can be cut into the polymer tube using a laser cutter. The laser cutter can include an eximer laser and CNC mechanism to position the stent under the laser. The stent pattern can be cut out in a configuration corresponding to the fully expanded state. The self-expanding polymer stent can be then physically compressed and loaded onto a delivery catheter equipped with a guidewire lumen and retractable sleeve for deployment of the stent. Using standard percutaneous techniques, this delivery catheter can be used to deliver and deploy the stent to stenosed vasculature where an ultimate size of approximately 3 mm is desired.
While particular embodiments of the present invention have been shown and described, it will be obvious to those skilled in the art that changes and modifications can be made without departing from this invention in its broader aspects. Therefore, the appended claims are to encompass within their scope all such changes and modifications as fall within the true spirit and scope of this invention.

Claims (11)

1. A coating for a medical device comprising:
a block copolymer having
a first block comprising a soft segment having a Tg below 37° C. wherein the soft segment is a reaction product of a spirodiketene acetal and a non-fouling moiety selected from the group consisting of a poly(alkylene glycol), poly(ethylene oxide-co-propylene oxide) (PLURONIC®), hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid and derivatives thereof, poly(2-hydroxyethyl methacrylate) and mixtures thereof; and,
a second block comprising a hard segment having a Tg above 37° C. wherein the hard segment is a reaction product of a spirodiketene acetal and a C2-C16 alkylene glycol, a cycloaliphatic diol, a cyclohexanedimethanol, and an oligoaliphatic diol selected from the group consisting of diethylene glycol, triethylene glycol or tetraethylene glycol.
2. A coating for a medical device wherein the coating comprises a polymer having the formula
Figure US07288609-20071030-C00008
wherein R and R1, are each independently a straight-chained, branched or cyclic alkyl radical C1-C8, or an aryl radical;
R2 is selected from the group consisting of methylene (—CH2—), poly(alkylene glycol), poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, derivatives of hyaluronic acid, poly(2-hydroxyethyl methacrylate), or mixtures thereof;
R3 is an aliphatic group;
m, n, p, and q are all integers, where the value of m is between 5 and 500, the value of n is between 2 and 350, the value of p is 1, and the value of q is between 10 and 550; and,
the “n” block has a Tg less than 37° C. and the “q” block has a Tg above 37° C.
3. The coating of claim 2, wherein R2 is methylene (—CH2—).
4. The coating of claim 2, wherein R2 is selected from the group consisting of poly(alkylene glycol), poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid, and poly(2-hydroxyethyl methacrylate).
5. The coating of claim 1 wherein the spirodiketene acetal is 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane (DPTOSH).
6. The coating of claim 1 wherein the medical device is a stent.
7. The coating of claim 1 wherein the non-fouling moiety is selected from the group consisting of poly(ethylene glycol), poly(propylene glycol), poly(tetramethylene glycol), hydroxylated poly(vinyl pyrrolidone), dextran, dextrin, hyaluronic acid and poly(2-hydroxyethyl methacrylate).
8. The coating of claim 1 wherein the alkylene glycol is selected from the group consisting of ethylene glycol, propylene glycol, butane-1,4-diol, pentane-1,5-diol, hexane-1,6-diol, heptane-1,7-diol, octane-1,8-diol, nonane-1,9-diol, decane-1,10-diol, undecane-1,11-diol, dodecane-1,12-diol, tridecane-1,13-diol, tetradecane-1,14-diol, pentadecane-1,15-diol, hexadecane-1,16-diol, butane-1,3-diol, pentane-2,5-diol and hexane-2,5-diol.
9. The coating of claim 1 wherein the spirodiketene acetal has the formula
Figure US07288609-20071030-C00009
wherein R and R1 are independently selected from the group consisting of straight-chained, branched, or cyclic alkyl radicals C1-C8, and aryl radicals.
10. The coating of claim 9 wherein the spirodiketene acetal is selected from the group consisting of 3,9-diethylidene-2,4,8,10-tetraoxaspiro-[5,5]-undecane, 3,9-dipentylidene-2,4,8,10-tetraoxaspiro-[5,5]-heptadecane, 3,9-dibutylidene-2,4,8,10-tetraoxaspiro-[5,5]-pentadecane and 3,9-dipropylidene-2,4,8,10-tetraoxaspiro-[5,5]-tridecane.
11. The coating of claim 9 wherein the alkylene glycol is selected from the group consisting of ethylene glycol, propylene glycol, butane-1,4-diol, pentane-1,5-diol, hexane-1,6-diol, heptane-1,7-diol, octane-1,8-diol, nonane-1,9-diol, decane-1,10-diol, undecane-1,11-diol, dodecane-1,12-diol, tridecane-1,13-diol, tetradecane-1,14-diol, pentadecane-1,15-diol, hexadecane-1,16-diol, butane-1,3-diol, pentane-2,4-diol and hexane-2,5-diol.
US10/382,197 2003-03-04 2003-03-04 Coatings for drug delivery devices based on poly (orthoesters) Expired - Fee Related US7288609B1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US10/382,197 US7288609B1 (en) 2003-03-04 2003-03-04 Coatings for drug delivery devices based on poly (orthoesters)
US11/859,372 US7588794B2 (en) 2003-03-04 2007-09-21 Coatings for drug delivery devices based on poly (orthoesters)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/382,197 US7288609B1 (en) 2003-03-04 2003-03-04 Coatings for drug delivery devices based on poly (orthoesters)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/859,372 Continuation US7588794B2 (en) 2003-03-04 2007-09-21 Coatings for drug delivery devices based on poly (orthoesters)

Publications (1)

Publication Number Publication Date
US7288609B1 true US7288609B1 (en) 2007-10-30

Family

ID=38623307

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/382,197 Expired - Fee Related US7288609B1 (en) 2003-03-04 2003-03-04 Coatings for drug delivery devices based on poly (orthoesters)
US11/859,372 Expired - Fee Related US7588794B2 (en) 2003-03-04 2007-09-21 Coatings for drug delivery devices based on poly (orthoesters)

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/859,372 Expired - Fee Related US7588794B2 (en) 2003-03-04 2007-09-21 Coatings for drug delivery devices based on poly (orthoesters)

Country Status (1)

Country Link
US (2) US7288609B1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080033140A1 (en) * 2006-06-29 2008-02-07 Alkatout Julie A Poly(orthoester) polymers, and methods of making and using same
US20080299164A1 (en) * 2007-05-30 2008-12-04 Trollsas Mikael O Substituted polycaprolactone for coating
US20090104241A1 (en) * 2007-10-23 2009-04-23 Pacetti Stephen D Random amorphous terpolymer containing lactide and glycolide
US20090110711A1 (en) * 2007-10-31 2009-04-30 Trollsas Mikael O Implantable device having a slow dissolving polymer
US20090259302A1 (en) * 2008-04-11 2009-10-15 Mikael Trollsas Coating comprising poly (ethylene glycol)-poly (lactide-glycolide-caprolactone) interpenetrating network
US20090297584A1 (en) * 2008-04-18 2009-12-03 Florencia Lim Biosoluble coating with linear over time mass loss
US20100291175A1 (en) * 2009-05-14 2010-11-18 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
US8052988B2 (en) 2003-11-06 2011-11-08 Advanced Cardiovascular Systems, Inc. Methods for fabricating coatings for drug delivery devices having gradient of hydration
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US8697113B2 (en) 2008-05-21 2014-04-15 Abbott Cardiovascular Systems Inc. Coating comprising a terpolymer comprising caprolactone and glycolide
US8916188B2 (en) 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US9090745B2 (en) 2007-06-29 2015-07-28 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
US9468706B2 (en) 2004-03-22 2016-10-18 Abbott Cardiovascular Systems Inc. Phosphoryl choline coating compositions
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US9539332B2 (en) 2004-08-05 2017-01-10 Abbott Cardiovascular Systems Inc. Plasticizers for coating compositions
US9737638B2 (en) 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
CN109568592A (en) * 2018-12-07 2019-04-05 安徽大学 A kind of nanogel NG1 and its application

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8527026B2 (en) 1997-03-04 2013-09-03 Dexcom, Inc. Device and method for determining analyte levels
US6001067A (en) 1997-03-04 1999-12-14 Shults; Mark C. Device and method for determining analyte levels
US20030032874A1 (en) 2001-07-27 2003-02-13 Dexcom, Inc. Sensor head for use with implantable devices
US7828728B2 (en) 2003-07-25 2010-11-09 Dexcom, Inc. Analyte sensor
JP4708342B2 (en) 2003-07-25 2011-06-22 デックスコム・インコーポレーテッド Oxygen augmentation membrane system for use in implantable devices
US8277713B2 (en) * 2004-05-03 2012-10-02 Dexcom, Inc. Implantable analyte sensor
US8744546B2 (en) 2005-05-05 2014-06-03 Dexcom, Inc. Cellulosic-based resistance domain for an analyte sensor
US8682408B2 (en) 2008-03-28 2014-03-25 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8583204B2 (en) 2008-03-28 2013-11-12 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US11730407B2 (en) 2008-03-28 2023-08-22 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US20090247855A1 (en) * 2008-03-28 2009-10-01 Dexcom, Inc. Polymer membranes for continuous analyte sensors
US8560039B2 (en) 2008-09-19 2013-10-15 Dexcom, Inc. Particle-containing membrane and particulate electrode for analyte sensors
US8183337B1 (en) 2009-04-29 2012-05-22 Abbott Cardiovascular Systems Inc. Method of purifying ethylene vinyl alcohol copolymers for use with implantable medical devices
JP2025509813A (en) * 2022-03-17 2025-04-11 イノコア テクノロジーズ ホールディング ビー．ブイ． Biodegradable thermoplastic poly(ortho ester)-based multiblock copolymers

Citations (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4977901A (en) 1988-11-23 1990-12-18 Minnesota Mining And Manufacturing Company Article having non-crosslinked crystallized polymer coatings
US5112457A (en) 1990-07-23 1992-05-12 Case Western Reserve University Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
EP0665023A1 (en) 1993-07-21 1995-08-02 Otsuka Pharmaceutical Factory, Inc. Medical material and process for producing the same
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US5667767A (en) 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US5670558A (en) 1994-07-07 1997-09-23 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
US5700286A (en) 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
US5824049A (en) 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
US5858746A (en) 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5865814A (en) 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US5971954A (en) 1990-01-10 1999-10-26 Rochester Medical Corporation Method of making catheter
US5980928A (en) 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
EP0970711A2 (en) 1998-06-30 2000-01-12 Ethicon, Inc. Process for coating stents
US6015541A (en) 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
WO2000012147A1 (en) 1998-09-02 2000-03-09 Scimed Life Systems, Inc. Drug delivery device for stent
US6042875A (en) 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US6051648A (en) 1995-12-18 2000-04-18 Cohesion Technologies, Inc. Crosslinked polymer compositions and methods for their use
US6056993A (en) 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US6080488A (en) 1995-02-01 2000-06-27 Schneider (Usa) Inc. Process for preparation of slippery, tenaciously adhering, hydrophilic polyurethane hydrogel coating, coated polymer and metal substrate materials, and coated medical devices
US6096070A (en) 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US6110188A (en) 1998-03-09 2000-08-29 Corvascular, Inc. Anastomosis method
US6113629A (en) 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
US6120904A (en) 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
WO2000064506A1 (en) 1999-04-23 2000-11-02 Agion Technologies, L.L.C. Stent having antimicrobial agent
US6165212A (en) 1993-10-21 2000-12-26 Corvita Corporation Expandable supportive endoluminal grafts
WO2001001890A1 (en) 1999-07-02 2001-01-11 Boston Scientific Limited Stent coating
US6822000B2 (en) * 2001-05-11 2004-11-23 Ap Pharma, Inc. Bioerodible poly (orthoesters) from dioxolane-based diketene acetals

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IN2014DN10834A (en) * 2001-09-17 2015-09-04 Psivida Inc

Patent Citations (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4733665C2 (en) 1985-11-07 2002-01-29 Expandable Grafts Partnership Expandable intraluminal graft and method and apparatus for implanting an expandable intraluminal graft
US4733665A (en) 1985-11-07 1988-03-29 Expandable Grafts Partnership Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft
US4733665B1 (en) 1985-11-07 1994-01-11 Expandable Grafts Partnership Expandable intraluminal graft,and method and apparatus for implanting an expandable intraluminal graft
US4800882A (en) 1987-03-13 1989-01-31 Cook Incorporated Endovascular stent and delivery system
US4886062A (en) 1987-10-19 1989-12-12 Medtronic, Inc. Intravascular radially expandable stent and method of implant
US4977901A (en) 1988-11-23 1990-12-18 Minnesota Mining And Manufacturing Company Article having non-crosslinked crystallized polymer coatings
US5971954A (en) 1990-01-10 1999-10-26 Rochester Medical Corporation Method of making catheter
US5328471A (en) 1990-02-26 1994-07-12 Endoluminal Therapeutics, Inc. Method and apparatus for treatment of focal disease in hollow tubular organs and other tissue lumens
US6060451A (en) 1990-06-15 2000-05-09 The National Research Council Of Canada Thrombin inhibitors based on the amino acid sequence of hirudin
US5112457A (en) 1990-07-23 1992-05-12 Case Western Reserve University Process for producing hydroxylated plasma-polymerized films and the use of the films for enhancing the compatiblity of biomedical implants
US5455040A (en) 1990-07-26 1995-10-03 Case Western Reserve University Anticoagulant plasma polymer-modified substrate
US5837228A (en) * 1990-08-22 1998-11-17 Merck & Co., Inc. Bioerodible implants
US5858746A (en) 1992-04-20 1999-01-12 Board Of Regents, The University Of Texas System Gels for encapsulation of biological materials
US5464650A (en) 1993-04-26 1995-11-07 Medtronic, Inc. Intravascular stent and method
US5716981A (en) 1993-07-19 1998-02-10 Angiogenesis Technologies, Inc. Anti-angiogenic compositions and methods of use
EP0665023A1 (en) 1993-07-21 1995-08-02 Otsuka Pharmaceutical Factory, Inc. Medical material and process for producing the same
US6165212A (en) 1993-10-21 2000-12-26 Corvita Corporation Expandable supportive endoluminal grafts
US5670558A (en) 1994-07-07 1997-09-23 Terumo Kabushiki Kaisha Medical instruments that exhibit surface lubricity when wetted
US5578073A (en) 1994-09-16 1996-11-26 Ramot Of Tel Aviv University Thromboresistant surface treatment for biomaterials
US5700286A (en) 1994-12-13 1997-12-23 Advanced Cardiovascular Systems, Inc. Polymer film for wrapping a stent structure
US6120904A (en) 1995-02-01 2000-09-19 Schneider (Usa) Inc. Medical device coated with interpenetrating network of hydrogel polymers
US6080488A (en) 1995-02-01 2000-06-27 Schneider (Usa) Inc. Process for preparation of slippery, tenaciously adhering, hydrophilic polyurethane hydrogel coating, coated polymer and metal substrate materials, and coated medical devices
US5605696A (en) 1995-03-30 1997-02-25 Advanced Cardiovascular Systems, Inc. Drug loaded polymeric material and method of manufacture
US6120536A (en) 1995-04-19 2000-09-19 Schneider (Usa) Inc. Medical devices with long term non-thrombogenic coatings
US5837313A (en) 1995-04-19 1998-11-17 Schneider (Usa) Inc Drug release stent coating process
US5873904A (en) 1995-06-07 1999-02-23 Cook Incorporated Silver implantable medical device
US5865814A (en) 1995-06-07 1999-02-02 Medtronic, Inc. Blood contacting medical device and method
US6129761A (en) 1995-06-07 2000-10-10 Reprogenesis, Inc. Injectable hydrogel compositions
US5824049A (en) 1995-06-07 1998-10-20 Med Institute, Inc. Coated implantable medical device
US6096070A (en) 1995-06-07 2000-08-01 Med Institute Inc. Coated implantable medical device
US5851508A (en) 1995-07-27 1998-12-22 Microtherapeutics, Inc. Compositions for use in embolizing blood vessels
US5667767A (en) 1995-07-27 1997-09-16 Micro Therapeutics, Inc. Compositions for use in embolizing blood vessels
US6051648A (en) 1995-12-18 2000-04-18 Cohesion Technologies, Inc. Crosslinked polymer compositions and methods for their use
US5968543A (en) * 1996-01-05 1999-10-19 Advanced Polymer Systems, Inc. Polymers with controlled physical state and bioerodibility
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5830178A (en) 1996-10-11 1998-11-03 Micro Therapeutics, Inc. Methods for embolizing vascular sites with an emboilizing composition comprising dimethylsulfoxide
US5980972A (en) 1996-12-20 1999-11-09 Schneider (Usa) Inc Method of applying drug-release coatings
US6042875A (en) 1997-04-30 2000-03-28 Schneider (Usa) Inc. Drug-releasing coatings for medical devices
US6056993A (en) 1997-05-30 2000-05-02 Schneider (Usa) Inc. Porous protheses and methods for making the same wherein the protheses are formed by spraying water soluble and water insoluble fibers onto a rotating mandrel
US5980928A (en) 1997-07-29 1999-11-09 Terry; Paul B. Implant for preventing conjunctivitis in cattle
US6121027A (en) 1997-08-15 2000-09-19 Surmodics, Inc. Polybifunctional reagent having a polymeric backbone and photoreactive moieties and bioactive groups
US6015541A (en) 1997-11-03 2000-01-18 Micro Therapeutics, Inc. Radioactive embolizing compositions
US6110188A (en) 1998-03-09 2000-08-29 Corvascular, Inc. Anastomosis method
US6113629A (en) 1998-05-01 2000-09-05 Micrus Corporation Hydrogel for the therapeutic treatment of aneurysms
US6153252A (en) 1998-06-30 2000-11-28 Ethicon, Inc. Process for coating stents
EP0970711A2 (en) 1998-06-30 2000-01-12 Ethicon, Inc. Process for coating stents
WO2000012147A1 (en) 1998-09-02 2000-03-09 Scimed Life Systems, Inc. Drug delivery device for stent
WO2000064506A1 (en) 1999-04-23 2000-11-02 Agion Technologies, L.L.C. Stent having antimicrobial agent
WO2001001890A1 (en) 1999-07-02 2001-01-11 Boston Scientific Limited Stent coating
US6822000B2 (en) * 2001-05-11 2004-11-23 Ap Pharma, Inc. Bioerodible poly (orthoesters) from dioxolane-based diketene acetals

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522217B2 (en) 2000-03-15 2016-12-20 Orbusneich Medical, Inc. Medical device with coating for capturing genetically-altered cells and methods for using same
US8088060B2 (en) 2000-03-15 2012-01-03 Orbusneich Medical, Inc. Progenitor endothelial cell capturing with a drug eluting implantable medical device
US8052988B2 (en) 2003-11-06 2011-11-08 Advanced Cardiovascular Systems, Inc. Methods for fabricating coatings for drug delivery devices having gradient of hydration
US8277926B2 (en) 2003-11-06 2012-10-02 Advanced Cardiovascular Systems, Inc. Methods for fabricating coatings for drug delivery devices having gradient of hydration
US8231962B2 (en) * 2003-11-06 2012-07-31 Advanced Cardiovascular Systems, Inc. Coatings for drug delivery devices having gradient of hydration
US9468706B2 (en) 2004-03-22 2016-10-18 Abbott Cardiovascular Systems Inc. Phosphoryl choline coating compositions
US9539332B2 (en) 2004-08-05 2017-01-10 Abbott Cardiovascular Systems Inc. Plasticizers for coating compositions
US8133968B2 (en) 2006-06-29 2012-03-13 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US7875697B2 (en) * 2006-06-29 2011-01-25 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US20110082275A1 (en) * 2006-06-29 2011-04-07 Medtronic, Inc. Poly(orthoester) polymers, and methods of making and using same
US20080033140A1 (en) * 2006-06-29 2008-02-07 Alkatout Julie A Poly(orthoester) polymers, and methods of making and using same
US8685430B1 (en) 2006-07-14 2014-04-01 Abbott Cardiovascular Systems Inc. Tailored aliphatic polyesters for stent coatings
US10155881B2 (en) 2007-05-30 2018-12-18 Abbott Cardiovascular Systems Inc. Substituted polycaprolactone for coating
US20080299164A1 (en) * 2007-05-30 2008-12-04 Trollsas Mikael O Substituted polycaprolactone for coating
US9737638B2 (en) 2007-06-20 2017-08-22 Abbott Cardiovascular Systems, Inc. Polyester amide copolymers having free carboxylic acid pendant groups
US9090745B2 (en) 2007-06-29 2015-07-28 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
US9468707B2 (en) 2007-06-29 2016-10-18 Abbott Cardiovascular Systems Inc. Biodegradable triblock copolymers for implantable devices
US9814553B1 (en) 2007-10-10 2017-11-14 Abbott Cardiovascular Systems Inc. Bioabsorbable semi-crystalline polymer for controlling release of drug from a coating
US20090104241A1 (en) * 2007-10-23 2009-04-23 Pacetti Stephen D Random amorphous terpolymer containing lactide and glycolide
US20090110711A1 (en) * 2007-10-31 2009-04-30 Trollsas Mikael O Implantable device having a slow dissolving polymer
US8642062B2 (en) 2007-10-31 2014-02-04 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US9629944B2 (en) 2007-10-31 2017-04-25 Abbott Cardiovascular Systems Inc. Implantable device with a triblock polymer coating
US8889170B2 (en) 2007-10-31 2014-11-18 Abbott Cardiovascular Systems Inc. Implantable device having a coating with a triblock copolymer
US9345668B2 (en) 2007-10-31 2016-05-24 Abbott Cardiovascular Systems Inc. Implantable device having a slow dissolving polymer
US20090259302A1 (en) * 2008-04-11 2009-10-15 Mikael Trollsas Coating comprising poly (ethylene glycol)-poly (lactide-glycolide-caprolactone) interpenetrating network
US8128983B2 (en) 2008-04-11 2012-03-06 Abbott Cardiovascular Systems Inc. Coating comprising poly(ethylene glycol)-poly(lactide-glycolide-caprolactone) interpenetrating network
US8475823B2 (en) 2008-04-18 2013-07-02 Medtronic, Inc. Baclofen formulation in a polyorthoester carrier
US8956642B2 (en) 2008-04-18 2015-02-17 Medtronic, Inc. Bupivacaine formulation in a polyorthoester carrier
US8940315B2 (en) 2008-04-18 2015-01-27 Medtronic, Inc. Benzodiazepine formulation in a polyorthoester carrier
US8916188B2 (en) 2008-04-18 2014-12-23 Abbott Cardiovascular Systems Inc. Block copolymer comprising at least one polyester block and a poly (ethylene glycol) block
US20090297584A1 (en) * 2008-04-18 2009-12-03 Florencia Lim Biosoluble coating with linear over time mass loss
US8697113B2 (en) 2008-05-21 2014-04-15 Abbott Cardiovascular Systems Inc. Coating comprising a terpolymer comprising caprolactone and glycolide
US8697110B2 (en) 2009-05-14 2014-04-15 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
US20100291175A1 (en) * 2009-05-14 2010-11-18 Abbott Cardiovascular Systems Inc. Polymers comprising amorphous terpolymers and semicrystalline blocks
CN109568592A (en) * 2018-12-07 2019-04-05 安徽大学 A kind of nanogel NG1 and its application
CN109568592B (en) * 2018-12-07 2021-08-24 安徽大学 A kind of nanogel NG1 and its application

Also Published As

Publication number Publication date
US20080071027A1 (en) 2008-03-20
US7588794B2 (en) 2009-09-15

Similar Documents

Publication Publication Date Title
US7588794B2 (en) Coatings for drug delivery devices based on poly (orthoesters)
US8277926B2 (en) Methods for fabricating coatings for drug delivery devices having gradient of hydration
US7455907B2 (en) Hydrophobic biologically absorbable coatings for drug delivery devices and methods for fabricating the same
US7005137B1 (en) Coating for implantable medical devices
EP1689462B1 (en) Coatings for implantable devices comprising block copolymers of lactic acid and ethylene glycol
EP1684821B1 (en) Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US8551446B2 (en) Poly(vinyl acetal) coatings for implantable medical devices
US7378106B2 (en) Biologically absorbable coatings for implantable devices and methods for fabricating the same
US7115300B1 (en) Method of coating implantable medical devices
US7803394B2 (en) Polycationic peptide hydrogel coatings for cardiovascular therapy
US20050186248A1 (en) Stent coating
US20060095122A1 (en) Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US20140147687A1 (en) Biologically absorbable coating for implantable devices based on copolymers having ester bonds and methods of fabricating the same
US9408949B2 (en) Coatings for implantable devices comprising polymers of lactic acid and methods for fabricating the same

Legal Events

Date Code Title Description
AS Assignment

Owner name: ADVANCED CARDIOVASCULAR SYSTEMS, INC., CALIFORNIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:PACETTI, STEPHEN D.;REEL/FRAME:013849/0511

Effective date: 20030303

STCF Information on status: patent grant

Free format text: PATENTED CASE

FPAY Fee payment

Year of fee payment: 4

FPAY Fee payment

Year of fee payment: 8

FEPP Fee payment procedure

Free format text: MAINTENANCE FEE REMINDER MAILED (ORIGINAL EVENT CODE: REM.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

LAPS Lapse for failure to pay maintenance fees

Free format text: PATENT EXPIRED FOR FAILURE TO PAY MAINTENANCE FEES (ORIGINAL EVENT CODE: EXP.); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20191030